Prasad S. Adusumilli, MD, FACS
Thoracic Surgeon & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Deputy Chief and Attending, Thoracic Service
- Vice Chair for Translational Research, Department of Surgery
- Co-Director, Mesothelioma Program
- Member, Solid Tumors Cell Therapy, Cellular Therapeutics Center
- Min H. & Yu-Fan C. Kao Chair in Thoracic Cancer
I am a surgeon with expertise in the diagnosis and treatment of thoracic cancers (cancers of the chest). These include lung cancer, mesothelioma, thymoma, mediastinal and chest wall tumors. I also specialize in cancers that have spread to the lung and pleura (layers of protective tissue that surround the lungs).
I see approximately 600 patients annually and have been caring for people with thoracic cancers for the past 15 years. I have expertise in the workup needed for the early diagnosis and accurate staging of thoracic cancers. For this, I use endoscopic methods such as endobronchial ultrasound (EBUS), robotic bronchoscopy, and video-assisted thoracoscopic surgery (VATS).
Read more
When newly diagnosed patients and their family members first meet me in the clinic, they are anxious. They can be overwhelmed by finding a treatment that will give them the best results and prevent the cancer from coming back. I take the time to explain the key factors that are driving the disease. We also discuss possible treatment options, the risks and benefits, and the expected short-term and long-term outcomes.
I like patients and family members to be reassured that we are considering every possible therapy and that we are focused on their quality of life. My goal is to help them feel confident in their care and be certain that we will treat them as a whole person — someone with a family, a job, and a desire not to be defined by their cancer diagnosis.
I work closely with thoracic pathologists, interventional radiologists, and pulmonologists to build a personalized treatment plan for each patient. My highly experienced clinical team includes a thoracic nurse and a nurse practitioner. We work together to deliver excellent care and provide personal attention to our patients and their family members.
As a surgeon and a scientist, I have a unique point of view. I treat patients and I study cancer in the lab. My research focuses on the development of biological markers to detect cancer that is at high-risk of coming back. I also study gene therapies, such as immunotherapy (enhancing patients’ own immune systems using genetic and cell engineering) and oncolytic viral therapy (killing cancer cells using genetically engineered viruses). I am working with my colleagues in medical and radiation oncology to use a combination of these treatments to help improve outcomes and lessen side effects.
Learn more about the accomplishments of the DoS.
My laboratory has led many discoveries about early-stage lung cancer and mesothelioma, and we have successfully used these findings to benefit patients. At their annual follow-up appointments after surgery, I make sure my patients are aware of these and other important developments that may help them.
Learn more about the Mesothelioma program at MSK.
Our immunotherapy research has led to clinical trials for people with mesothelioma, lung cancer, and esophageal cancer (protocols 15-007, 16-040 and 20-328). This work is supported by the National Cancer Institute, the Department of Defense, the American Association for Cancer Research, the International Association for the Study of Lung Cancer, and several other foundations.
I am also honored to mentor surgical trainees and research fellows. The high quality of their training is reflected in their presentations at national and international conferences and submissions to peer-reviewed publications.
In my spare time, I love to write and have published several satirical science fiction articles. I also enjoy cooking for my family and children and traveling internationally, especially visiting friends in rural areas of Europe.
A thoracic (thor-A-sik) surgeon is a doctor with special training in surgery on the chest, lungs, trachea (windpipe), and thymus.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Lung Cancer
- Mesothelioma
- Metastatic Cancers to the Lung
- Mediastinal and Chest Wall Tumors
- Thymoma
- Pleurectomy
- Video-assisted thoracic Surgery (VATS)
- Lobectomy
- Robotic Bronchoscopy
- Laparoscopy
Education
- MD, Guntur Medical College, India
Residencies
- Surgery - Southampton University Hospitals, UK
- General Surgery - Maimonides Medical Center
- General Surgery - Lenox Hill Hospital
Fellowships
- Cardiothoracic Surgery - Maimonides Medical Center
- Thoracic Surgery - Memorial Sloan Kettering Cancer Center
- Cardiothoracic Surgery - University of Pittsburgh Medical Center
Board Certifications
- Thoracic Surgery
- General Surgery
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Adusumilli sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Clinical Trials
- Clinical Trials Investigated by Dr. Adusumilli
- A Study of Tumor-Treating Fields (TTFields) in People with Lung Adenocarcinoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Patient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Prasad S. Adusumilli discloses the following relationships and financial interests:
-
Abound Bio
Professional Services and Activities -
Adjuvant Genomics, Inc.
Equity; Professional Services and Activities (Uncompensated) -
Affyimmune Therapeutics, Inc.
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
Atara Biotherapeutics
Intellectual Property Rights; Professional Services and Activities -
Bayer
Professional Services and Activities -
BioArdis LLC
Professional Services and Activities -
CARISMA Therapeutics Inc.
Professional Services and Activities -
Century Therapeutics
Professional Services and Activities -
Crescendo Biologics Limited
Professional Services and Activities -
Emerson Collective
Professional Services and Activities -
FirstThought, LLC
Professional Services and Activities -
Galapagos NV
Professional Services and Activities -
Guidepoint Global Advisors
Professional Services and Activities
-
ImmPACT Bio USA Inc.
Professional Services and Activities -
Imugene Limited
Professional Services and Activities -
Johnson & Johnson
Professional Services and Activities -
Kineticos
Professional Services and Activities -
MJH Life Sciences
Professional Services and Activities -
Novocure
Professional Services and Activities -
Orion Corporation
Professional Services and Activities -
Outpace Bio, Inc.
Professional Services and Activities -
Pluri Biotech Ltd.
Professional Services and Activities -
Society for Immunotherapy of Cancer
Professional Services and Activities -
Takeda Pharmaceuticals
Professional Services and Activities -
University of Pittsburgh
Professional Services and Activities -
Verismo Therapeutics, Inc.
Professional Services and Activities -
WC Communications, LLC
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].